@article{fdi:010077468,
  title = {{P}eptide-based vaccine successfully induces protective immunity against canine visceral leishmaniasis},
  author = {{P}etitdidier, {E}lodie and {P}agniez, {J}ulie and {P}issarra, {J}. and {H}olzmuller, {P}. and {P}apierok, {G}. and {V}incendeau, {P}. and {L}emesre, {J}ean-{L}oup and {B}ras {G}oncalves, {R}achel},
  editor = {},
  language = {{ENG}},
  abstract = {{D}ogs are the main reservoir of zoonotic visceral leishmaniasis. {V}accination is a promising approach to help control leishmaniasis and to interrupt transmission of the {L}eishmania parasite. {T}he promastigote surface antigen ({PSA}) is a highly immunogenic component of {L}eishmania excretory/secretory products. {A} vaccine based on three peptides derived from the carboxy-terminal part of {L}eishmania amazonensis {PSA} and conserved among {L}eishmania species, formulated with {QA}-21 as adjuvant, was tested on naive {B}eagle dogs in a preclinical trial. {F}our months after the full course of vaccination, dogs were experimentally infected with {L}eishmania infantum promastigotes. {I}mmunization of dogs with peptide-based vaccine conferred immunity against experimental infection with {L}. infantum. {E}vidence for macrophage nitric oxide production and anti-leishmanial activity associated with {IFN}-y production by lymphocytes was only found in the vaccinated group. {A}n increase in specific {I}g{G}2 antibodies was also measured in vaccinated dogs from 2 months after immunization. {A}dditionally, after challenge with {L}. infantum, the parasite burden was significantly lower in vaccinated dogs than in the control group. {T}hese data strongly suggest that this peptide-based vaccine candidate generated cross-protection against zoonotic leishmaniasis by inducing a {T}h1-type immune response associated with production of specific {I}g{G}2 antibodies. {T}his preclinical trial including a peptide-based vaccine against leishmaniasis clearly demonstrates effective protection in a natural host. {T}his approach deserves further investigation to enhance the immunogenicity of the peptides and to consider the possible engineering of a vaccine targeting several {L}eishmania species.},
  keywords = {},
  booktitle = {},
  journal = {{NPJ} {V}accines},
  volume = {4},
  numero = {},
  pages = {art. 49 [9 ]},
  year = {2019},
  DOI = {10.1038/s41541-019-0144-2},
  URL = {https://www.documentation.ird.fr/hor/fdi:010077468},
}